cyrilzakka/clinical-trials huggingface dataset:
The Role of Agency and Threat-Immediacy in Interactive Digital Narrative Fear Appeals

Aims:

The first aim of the study was to assess the effect of agency, i.e. the perception of making meaningful decisions, in an interactive digital narrative fear appeal on self-efficacy beliefs concerning the ability to reduce alcohol intake among college students. Second, we assessed whether the communicated timeframe (short-term / long-term) of the threat presented in the narrative moderates the effect of agency on self-efficacy. Lastly, to validate the effect of the intervention on behavioural outcomes we assesed whether self-efficacy has an effect on behavioural intention measures.

The study was a 2 (agency: low / high) x 2 (time-frame: immediate / distant) between-subjects online experiment.


Eligibility Criteria:
Inclusion Criteria:

* above 18 years of age
* 480 seconds survey completion time
* both attention checks relating to narrative content passed
* correctly identified their experimental condition in the manipulation check
* did not choose to 'drink an alcoholic drink' for all decisions in the interactive narrative
* did not show signs of alcohol abuse

Exclusion Criteria:

* under the age of 18
* completed the questionnaire in an unreasonably short amount of time
* they failed one of the two attention checks
* failed the manipulation check asking them to recall whether they were presented with short- or long-term (high / low immediacy) consequences of excessive drinking
* chose an alcoholic drink for all decision points
* showed signs of alcohol dependence as measured above 15 on the Brief Young Adult Alcohol Consequences Questionnaire (B-YAACQ)
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

In this clinical trial, the testing kit to be evaluated is a Human Multigene Methylation Detection Kit (Fluorescent PCR Method), which is intended to qualitatively detect methylation levels of multiple genes in human sputum specimen in vitro by Fluorescent PCR Method, and the standard method used in clinical diagnosis is chest CT examination or pathological examination.

Subjects will provided sputum specimen as required for the evaluation of the testing kit followed by a chest CT examination or pathological examination. Technical personnel who conduct the evaluation of the testing kit will remain blinded to the results of the clinical diagnosis by chest CT and/or pathological examination.

The results of the testing kit will be compared with the standard method, and the effectiveness of the Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for lung cancer detection under normal clinical use will be assessed through statistical analysis.

Eligibility Criteria:
Inclusion Criteria:

* Subject must meet all three of the following criteria to be eligible for the study:

  1. No age or gender restrictions, voluntary participation and signing of informed consent form;
  2. Meet any of the following conditions:

  <!-- -->

  1. Suspected of lung cancer without invasive examination;
  2. Diagnosed with lung cancer without surgery, radiotherapy, chemotherapy, or targeted therapy;
  3. Diagnose other respiratory diseases, such as pulmonary infections (bacterial pneumonia, mycoplasma pneumonia, chlamydia pneumonia, viral pneumonia, lung abscess, etc.), interstitial lung diseases (pulmonary fibrosis, pulmonary granulomas, etc.), benign pulmonary nodules, tuberculosis, emphysema, pulmonary cysts, benign pulmonary tumors, obstructive pulmonary disease, bronchial infections/asthma, acute upper respiratory tract infections, etc;
  4. Diagnose other malignant tumors, such as thyroid cancer, esophageal cancer, liver cancer, gastric cancer, pancreatic cancer, etc.

Exclusion Criteria:

* Any of the following conditions must be excluded:

  1. Patients who have undergone tracheotomy or have been on a ventilator due to severe illness.
  2. The research physician believes that other reasons are not suitable for participants in this trial.
Prevalence and Outcome of Hypermetabolism in Initial Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study

Patients in critical illness frequently present hypermetabolism， which can extremely increase the rest energy expenditure（REE）. We hypothesize that if we alleviate the extremely increased REE will improve ICU patients' outcome

This study focuses on the early changes of REE of critical ill patients when they admitted to ICU.

Eligibility Criteria:
Inclusion Criteria:

* Older than 18 year.
* APACHEⅡ score≥8

Exclusion Criteria:

* Hypercortisolism
* Thyroid disease
* Tracheoesophageal fistula
* FiO2\>60 or PEEP\>12cm H2O in mechanical ventilate
* Pregnancy
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects

Primary Purpose of this study is to compare the pharmacokinetic (PK) of Abatacept (BMS-188667) manufactured at Lonza relative to Abatacept (BMS-188667) manufactured at Devens, MA facility following a single intravenous infusion of 750 mg in healthy subjects

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations
* Body weight will be between 60 and 100 kg, inclusive

Exclusion Criteria:

* Any significant acute or chronic medical illness
* Any major surgery within 4 weeks of study drug administration
* Smoking more than 10 cigarettes per day
* Recent (within 6 months of study drug administration) drug or alcohol abuse.
* Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus-1, Human Immunodeficiency Virus-2 antibody
* History of any significant drug allergy or asthma
* Women who are pregnant or breastfeeding and/or unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
Evaluation of the Association Between Depression and Glycemic Control in People With Type 1 Diabetes

Single-center prospective observational pilot study

The aim of the study is to evaluate the potential association between the percentage of time spent in the optimal glycemia range and the score obtained in the questionnaires used to screen for depression.

The study involves only one visit for each participant. Each participant will be asked to sign the informed consent to the study and, during the visit, the following information will be acquired: parameters, history of diabetes, concomitant diseases and medications, and CGM metrics.

The participant will be administered the following questionnaires for the evaluation of depression, patient-reported outcome measure (PROMs) and treatment satisfaction:

* Patient Health Questionnaire (PHQ-9)
* Center of Epidemiological Studies-Depression Scale (CES-D)
* Diabetes Treatment Satisfaction Questionnaire (DTSQ)
* Well-Being Index (WHO-5)
* Problem Areas In Diabetes (PAID-5)
* European Quality of Life, Five Dimension, Five Level (EQ5D5L)


Eligibility Criteria:
Inclusion Criteria:

1. Informed consent before any activity foreseen by the protocol
2. Age \> 18 years
3. Subjects with type 1 diabetes mellitus, both on multiple daily injection and with insulin pump, using glucose monitoring systems, both flash glucose monitoring and continuous glucose monitoring

Exclusion criteria:

1. Type 2 diabetes mellitus or other forms of diabetes, such as steroid-induced or secondary to pancreatectomy, pancreatitis, or secondary to endocrinological disorders
2. Previous diagnosis of major depression, bipolar disorder, psychotic disorder, eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder)
3. Chronic treatment with corticosteroids
4. BMI \<19kg/m2
5. Known history of substance or alcohol abuse
6. Patients who have recently been admitted to the psychiatry ward or are being treated with psycho-drugs
7. Conditions that do not allow participation in the activities envisaged by the protocol
Distal Transradial Access for Percutaneous Coronary Intervention

Prospective randomized non-blinded study to determine degree of vessel trauma and adverse remodeling of the proximal forearm radial artery following distal radial artery access (dTRA) for cardiac catheterization compared to standard forearm transradial access (fTRA).

To determine degree of vessel trauma and adverse remodeling of the proximal forearm radial artery, using ultrahigh resolution (55 MHz) ultrasound, following distal radial artery access (dTRA) for cardiac catheterization compared to standard forearm transradial access (fTRA) at 90 days post-procedure. Secondary outcome measures will include metrics of procedural success at 24 hours, as well as functional assessment of pain and motor strength of the ipsilateral upper extremity at 90 days post-procedure.

Eligibility Criteria:
Inclusion Criteria:

1. Consecutive patients undergoing elective and non-emergent TR LHC and/or PCI at the INOVA Heart and Vascular Institute
2. Able to provide informed consent.
3. Patients willing to complete a 90day post PCI radial artery ultrasound.

Exclusion Criteria:

1. Patients with previous cannulation of both the right and left forearm RA's for coronary angiography and/or PCI. In patients with prior cannulation of one RA, the contralateral arm may be used for this study.
2. Patients who are not willing to undergo the necessary follow-up ultrasound examinations.
3. ST elevation myocardial infarction or other emergent PCI
4. Inability to provide informed consent
Prevalence of Angle Closure in Caucasian Hyperopes

The primary purpose of this study is to assess the prevalence of asymptomatic chronic angle closure in high risk Caucasian individuals, namely those with hyperopia. A secondary purpose is to assess whether specific demographic or ocular-anatomic parameters in this population are associated with a higher risk for angle closure.

Caucasian subjects aged \> 40 years with hyperopia will undergo complete eye examination including subjective refraction and gonioscopy. In addition we will measure axial length, anterior chamber depth and lens thickness using ultrasound biometry.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 40 years
* Hyperopia greater then +1.00 D spherical equivalent

Exclusion Criteria:

* Any identifiable eye disease or previous eye surgery that can affect the anatomy of the irido-corneal angle
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

The purpose of this study is to determine whether the treatment of Alemtuzumab in combination with CHOP(cyclophosphamide,doxorubicin,vincristine and prednisolone) are effective as first line treatment in patients with peripheral T-cell lymphoma.

Peripheral T-cell lymphomas (PTCL) are more common in Asia than in Europe and United States (17-40% vs. 5-10%). Most studies reported a poorer prognosis for PTCL compared to B-cell non-Hodgkin's lymphomas (NHL).

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as a standard chemotherapy regimen for patients with newly diagnosed NHL.

Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell surface protein present at high density on most normal and malignant B and T lymphocytes.Malignant T cells express particularly high numbers of CD52 cell surface markers (approximately 500,000 molecules/lymphocytes),T-cell malignancies may thus be particularly responsive to alemtuzumab.

As the response rate tend to be higher in patients newly diagnosed with PTCL, this study evaluates the efficacy of alemtuzumab in combination with CHOP administered as up-front therapy in patients newly diagnosed with PTCL in terms of response rate and overall survival.

Eligibility Criteria:
Inclusion Criteria:

* Patients must have a diagnosis of one of the following histologic types according to the WHO classification:

  * Angioimmunoblastic T-cell lymphoma
  * Extranodal NK/T-cell lymphoma,nasal type
  * Enteropathy-type T-cell lymphoma
  * Hepatosplenic gamma-delta T-cell lymphoma
  * Subcutaneous panniculitis-like T-cell lymphoma
  * Anaplastic large-cell lymphoma,T/null cell,primary systemic type
  * Peripheral T-cell lymphoma,not otherwise characterized
* Newly diagnosed,age 15-65 years.
* Complete work up for baseline evaluation and measurement (Appendix B)
* Patient's free written inform consent.

Exclusion Criteria:

* Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab.
* Patients who have received prior antilymphoma treatment with chemotherapy or radiotherapy
* Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).
* Serologic evidence of HCV and HCV RNA of chronic hepatitis.
* Serologic evidence of HBV and HBV RNA of chronic hepatitis.
* Patients with history of impaired cardiac status or myocardial infarction.
* Patients with serum creatinine \>= 1.8 mg/dl,bilirubin \>= 1.5 times upper limit of normal range,SGOT or SGPT \>= 3 times upper limit of normal range, unless due to tumor involvement.
* Patients with active uncontrolled infection,active non-malignant gastric or duodenal ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would preclude aggressive cytotoxic chemotherapy.
* Active secondary malignancy.
* Pregnant or lactating women.
* Serious medical or psychiatric illness which prevent informed consent.
* Patients who are likely to lost to follow up (eg, unwilling or difficult to return,cannot be contacted).
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse cohort of people with SMA (pwSMA) and evaluate the change of PPF before and after nusinersen dosing.

Fatigue and fatigability are symptoms often experienced by people living with spinal muscular atrophy (pwSMA). Nusinersen is shown to extend survival and improve motor function, but fatigue and fatigability persist. Treated patients report changes in their ability to complete repetitive physical activities but a way for measuring this has not been created. While tests completed in the clinic by individuals with SMA highlight that fatigability is an important part of the SMA experience,we do not fully understand how pwSMA experience fatigability with everyday tasks. Anecdotal reports of pwSMA suggest a waning effect in endurance toward the end of their treatment window, however this change has not been measured.The SMA EFFORT is specifically designed for pwSMA and aims to better understand how they feel when completing daily physical activities.

Eligibility Criteria:
Inclusion Criteria:

1. All types of 5qSMA (homozygous deletion or point mutation of the SMN1 gene and any number of SMN2 copies)
2. Receiving a stable dosing regimen of 12mg nusinersen for at least 6 months

Exclusion Criteria:

1. An injury or surgery within the previous 3 months that would impact their ability to perform in-clinic function and/or fatigability assessments
2. Enrolled in an ongoing clinical trial, or extension study, expanded access program, or long-term registry of an investigational or recently approved medication
3. Receiving adjuvant and/or dual therapy (e.g., muscle-targeted, NMJ, or symptomatic treatments)
Repeated Food Exposure Via the Olfactory and Gustatory Systems

Increasing exposure to a single orosensory cue without ingestion of additional energy may promote an increased rate of habituation, more rapid satiation, and reduced intake. This exposure can occur via smell (olfactory) and taste (gustatory) systems.It is not clear if repeated exposure via the combined olfactory and gustatory systems increases the rate of habituation more so than repeated exposure through one of these systems. Thus, the purpose of this investigation is to examine the amount of salivation occurring in 12 trials of exposure to a food via the olfactory, gustatory, and combined olfactory and gustatory systems. The primary dependent variable will be the amount of salivation in the 12 trials. It is hypothesized that a more rapid decrease in salivation will occur across trials in the combined olfactory and gustatory exposure as compared to the other two conditions, indicating a more rapid rate of habituation.

Approximately two of every three adults in the U.S. are overweight or obese. The high prevalence of overweight/obesity negatively affects the health of the population, as obese individuals are at increased risk for developing several chronic diseases.

Successful control of body weight depends on effectively regulating eating. Satiation, the process by which an eating bout ends, assists with eating regulation, and factors that quicken the onset of satiation may aid with decreasing intake. One factor believed to influence satiation is the rate of decrease in consummatory response (habituation) to repeated presentations of food orosensory cues. Habituation is a basic form of learning, in which behavioral and physiological responses decrease in response to repeated presentations of a stimulus, with the decrease in response unrelated to sensory adaptation/fatigue or motor fatigue.

In one condition, participants will smell lemon and lime across 12 trials (olfactory exposure), in another condition participants will taste the juices across 12 trials (gustatory exposure), and in the last condition participants will smell and taste the juices across 12 trials (olfactory + gustatory exposure). The primary dependent variable will be the amount of salivation in the 12 trials. It is hypothesized that a more rapid decrease in salivation will occur across trials in the combined olfactory and gustatory exposure as compared to the other two conditions, indicating a more rapid rate of habituation

Eligibility Criteria:
Inclusion Criteria:

* Dietary restraint scores of less than or equal to 12 on the Three Factor -
* Eating Questionnaire-Cognitive Restraint scale.
* Have a body mass index (BMI) between 18.5 and 24.9.

Exclusion Criteria:

* Are taking medications or having an illness which might influence salivation, smell, and taste (i.e. upper respiratory illness, methylphenidate, atropine, Benadryl, Elavil, etc)
* Are currently dieting
* Are a binge eater
* Do not at least moderately like lemon or lime flavor scoring \< 50 on a 100 mm visual analogue scale
* Are a regular smoker
* Have any dietary restrictions that will inhibit participation including food allergies
Antiretroviral Therapy Selection: Comparing HIV Clinical Guidelines With HIV-ASSIST, an Online Decision-support Tool

HIV-ASSIST is an online decision support tool created by Johns Hopkins faculty that utilizes standard patient variables, and provides treatment recommendations and tailored educational content to assist providers learn HIV treatment principles and support decision-making.

The research goal is to determine the difference in percentage of appropriate antiretroviral therapy (ART) selection (based upon a reference standard of HIV experts and guidelines) for a set of hypothetical patient scenarios, comparing a group of trainees with access to current national DHHS guidelines (control), and a group using HIV-ASSIST (intervention) in addition to guidelines.

The investigators proposed a randomized study design, in which an electronic survey/questionnaire with 10 HIV case vignettes are presented to study participants. Medical and nursing students and internal medicine residents will be eligible to participate.

Participants providing informed consent will be randomized to receiving access to either online Department of Health and Human Services (DHHS) HIV guidelines, or the HIV-ASSIST online tool to support participants' decision making. Participants will be asked to indicate participants' ART regimen of choice for each case scenario. The proportion of appropriate ART selections will be evaluated comparing the intervention and control arms. The investigators will additionally report the time required for trainees to complete ART selections for the presented clinical vignettes.


Eligibility Criteria:
Inclusion Criteria:

* Students in the Johns Hopkins Schools of Medicine or Nursing, and/or internal medicine residents

Exclusion Criteria:

* None
Non Contrast MRI in Lower Extremity

We collected retrospectively the non contrast MRI in chia yi memorial hospital for different venous disease of lower extremity morphology and flow ananlysis were done.

Retrospective, analysis of the venous figure by TRANCE MRI no drug/contrast median usage no radiation toxicity the range from the pelvic to the toe

Eligibility Criteria:
Inclusion Criteria:

* possible venous disease no contraindication for mri

Exclusion Criteria:

* could not tolerate mri packemaker
Albumin Kinetics in Generalized Inflammation

The purpose of this study is to determine whether the kinetics of endogenous albumin is altered by the generalized inflammation caused by major abdominal surgery.

Albumin infusions have been used for expansion of the plasma volume for more than 60 years, not only in the operating room, but also in trauma and sepsis. However, there is an ongoing debate whether albumin is good or bad for the patient compared to other intravenous fluids, in different situations. Our research program aims at exploring this issue, starting by describing how the body handles the endogenous albumin in connection with severe inflammation. The final goal is to improve fluid treatment for these patients.

Plasma albumin is often decreased in inflammation. However, the underlying mechanisms are not well described. Two aspects of albumin kinetics will be covered in this study by measurements immediately before and two days after major abdominal surgery, that will serve as a model for generalized inflammation. Albumin fractional synthesis rate will be determined by the incorporation of deuterium labelled phenylalanine into plasma albumin. Albumin distribution will be measured as transcapillary escape rate of radioiodinated albumin. By assessment of P-albumin and plasma volume it will be possible to calculate albumin absolute rate of synthesis and albumin absolute flux from the central compartment, respectively.

Eligibility Criteria:
Inclusion Criteria:

* written informed consent
* patients planned for major abdominal surgery, pancreatic
* age ≥ 40 years

Exclusion Criteria:

* pregnant or lactating patients
* planned peri-operative infusions of albumin or plasma
* S-creatinine \> 110 mmol/L
* allergy against iodine
* other conditions preventing the subject from participating in the study, as judged by the investigator